BMS terminates collaboration with Century Therapeutics without cause; effective March 12, 2025

Century Therapeutics, Inc.

BMS notified Century on Dec 12, 2024 of termination of the 2022 Research, Collaboration and License Agreement.
Termination covers all iPSC-derived NK and gamma delta T cell programs for hematologic malignancies.
Century will evaluate opportunities in AML and multiple myeloma under ongoing strategic review of pre-clinical pipeline.
Both parties will cooperate on termination provisions; no financial details of termination disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.